After the cure: Management of HCV after achievement of SVR

Current HIV/AIDS Reports

Volumn 10, Issue 4, 2013, Pages 428-435

  Zator, Zachary A ^a   Chung, Raymond T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Carcinoma, Hepatocellular; Coinfection drug therapy; Elasticity imaging techniques; End stage liver disease etiology; Hepatitis C, Chronic drug therapy; Hepatitis C, Chronic epidemiology; Hepatitis C, Chronic virology; HIV infections; Humans; Liver cirrhosis physiopathology; Liver cirrhosis complications; Liver cirrhosis mortality; Liver cirrhosis virology; Liver diseases prevention control; Liver diseases virology; Tissue elasticity imaging; Treatment outcome

Indexed keywords

ARTICLE; DISEASE COURSE; ESOPHAGUS VARICES; GASTROESOPHAGEAL VARICES; HEPATITIS C; HUMAN; INFECTION RISK; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH VARICES; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; COINFECTION; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC;

EID: 84891148248     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0181-9     Document Type: Article

References (52)

1. Staples Jr CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veteran Affairs Medical Center) Cohort Study (HAVACS): the effect of co-infection on survival. Clin Infect Dis. 1999;29:150.
2. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr. 2001;26:466.
3. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197-207.
4. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology. 2006;44:1675-84.
5. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-41.
6. der Meer V et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. In those with HCV and advanced fibrosis, SVR resulted in a significant decrease in HCC, all-cause mortality, and hepatic mortality.
7. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5.1):329-37.
8. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407-13.
9. Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20:2361-9.
10. Poynard T, McHutchinson J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303-13.
11. Camma C, Di Bona D, Schepis F, Heathcote EJ, Zeuzem S, Pockros PJ, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology. 2004;39:333-42.
12. RodrIguez-Torres M, RodrIguez-Orengo JF, RIos-Bedoya CF, Fernandez-Carbia A, Gonzalez-Lassalle E, Salgado-Mercado R, et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol. 2007;38:32-8.
13. Chapplain J, Bellissant E, Guyader D, et al. The effects of a maintenance therapy with peg-interferon alpha-2a on liver fibrosis in HIV/HCV co-infected patients: a randomized controlled trial. J Infect. 2013;67:313-21.
14. Veldt BJ, Heathcote J, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Int Med. 2007;147:677-84.
15. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833-44. This study showed that SVR in chronic HCV results in marked reductions in death, liver transplantation, and liver-related morbidity and mortality, but does not eliminate the risk of HCC.
16. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-21. This group constructed and up to date natural history model that showed that the grade of fibrosis in chronic HCV is increasing in severity and is projected to continue doing so.
17. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726.
18. Myers RP, De Torres M, Imbert-Bismut F, et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci. 2003;48:146.
19. Myers RP, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS. 2003;17:721.
20. Rossi E, Adams L, Prins A, et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003;49:450.
21. Halfon P, Bourliere M, Deydier R, et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol. 2006;101:547.
22. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007;5:1214.
23. Merchante N, Rivero-Juárez A, Téllez F, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology. 2012;56:228.
24. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343.
25. Pineda JA, Aguilar-Guisado M, Rivero A, et al. Natural history of compensated hepatitis C-virus related cirrhosis in HIV-infected patients. CID. 2009;49:1274-82.
26. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-31.
27. Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005;41:779-89.
28. Jang JY et al. HIV infection increases HCV-induced hepatocyte apoptosis. J Hepatol. 2011;54(4):612-20.
29. de Franchis R. Evolving consensus in portal hypertension report of the baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167-76.
30. Sanyal AJ, Fontana RJ, DiBisceglie AM, Everhart JE, Doherty MC, Everson GT, et al. and the HALT-C trial group. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc. 2006;64:855-64.
31. Garcia-Tsao G, Sanyal AJ, Grace ND, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922-38.
32. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. for the Portal Hypertension Collaborative Group. Betablockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254-61.
33. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983-9.
34. D'Ambrosi R, Aghemo A, Rumi MG, et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther. 2011;16(5):677-84.
35. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69.
36. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-91.
37. Davila JA, Morgan RO, Shaib Y, et al. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127:1372.
38. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37 Suppl 2:S88-94.
39. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-70.
40. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55:1344-55.
41. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285.
42. Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527.
43. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2.
44. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136(1):138.
45. Limketkai BN, Mehta SH, Sutcliffe CG, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;208(4):370-8.
46. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol. 2006;80:1197-213.
47. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-50.
48. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet. 1998;351:214-5.
49. Zeuzem S, Heathcote E, Shiffman M, et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol. 2003;39:106-11.
50. Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. CID. 2009;49:1397-401.
51. Martin T, Martin NK, Hickman M, et al. HCV reinfection incidence and treatment outcome among HIV-positive MSM in London. AIDS 2013;27:000-000.
52. Innes HA, Hutchinson SJ, Allen S, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011;54:1547-58.